

Yonina R Murciano-Goroff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1929572/publications.pdf>

Version: 2024-02-01

14
papers

1,213
citations

1040056

9
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

2118
citing authors

#	ARTICLE	IF	CITATIONS
1	An Ascendant Challenge: Central Nervous System Metastases in <i>ALK</i> + Lung Cancers. <i>Clinical Cancer Research</i> , 2022, 28, 2477-2479.	7.0	1
2	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. <i>British Journal of Cancer</i> , 2022, 126, 889-898.	6.4	8
3	The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies. <i>Cancer Cell</i> , 2021, 39, 22-24.	16.8	16
4	<i>KRAS</i> G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2604-2612.	7.0	20
5	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. <i>Oncologist</i> , 2021, 26, 514-522.	3.7	18
6	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. <i>Lung Cancer</i> , 2021, 159, 66-73.	2.0	17
7	Diverse alterations associated with resistance to <i>KRAS</i> (G12C) inhibition. <i>Nature</i> , 2021, 599, 679-683.	27.8	183
8	Chemotherapy and COVID-19 Outcomes in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3538-3546.	1.6	195
9	EGFR Blockade Reverts Resistance to <i>KRAS</i> G12C Inhibition in Colorectal Cancer. <i>Cancer Discovery</i> , 2020, 10, 1129-1139.	9.4	245
10	The future of cancer immunotherapy: microenvironment-targeting combinations. <i>Cell Research</i> , 2020, 30, 507-519.	12.0	480
11	Toward a More Precise Future for Oncology. <i>Cancer Cell</i> , 2020, 37, 431-442.	16.8	21
12	Medical oncologists' willingness to participate in bundled payment programs. <i>BMC Health Services Research</i> , 2018, 18, 391.	2.2	1
13	Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 173-180.	2.5	4
14	Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3096-3096.	1.6	4